GNVR 最新10-Q变化
将 GNVR 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-13
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +44 | −33 | ~8 | 10 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | +20 | −8 | ~3 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Genvor, through its wholly-owned subsidiary, Genvor Inc., is developing an AI-enabled peptide platform focused on proprietary peptide candidates for agricultural crop protection, crop optimization and related health and wellness applications. The Company’s most advanced scientific foundation is its …
The Company’s peptide technology has advanced from in vitro testing into transgenic maize greenhouse studies. Peer-reviewed published data showed that the Company’s peptides reduced growth of numerous bacterial and fungal pathogens, and that its lead product candidates, AGM182, GV185 and GV187, redu…
The Company also intends to use its peptide library and its AI-enabled peptide design platform, BioCypher, to further design, identify, optimize and license peptide candidates to third parties, including potential partners in agriculture and human health and wellness. In human health and wellness, t…
Over the next four years, the Company intends to focus on researching and developing portfolio solutions for the following:
● Insecticides: insecticidal peptides to control key insects and nematodes; and
相对上期删除的文字 · 来源:10-Q · 2026-05-13
Genvor, through its wholly-owned subsidiary, Genvor Inc., is pioneering the development and commercialization of AI-accelerated peptide technology to address critical challenges across two markets: agricultural biologicals and human health and wellness. Management believes Genvor’s proprietary AI-ac…
With respect to agriculture, antimicrobial peptides (“AMPs”) are intended to provide broad-spectrum protection against fungal, bacterial, and viral pathogens that threaten crop productivity worldwide while nutritionally enhanced peptides (“NEPs”) are intended to optimize nutrient uptake and utilizat…
These peptide technologies are distinguished by their multiple modes of action and biodegradability, which are intended to significantly reduce the risk of resistance development that increasingly limits the effectiveness of conventional chemical pesticides. The Company’s solutions are intended to m…
The Company’s strategic vision extends beyond crop protection to encompass the broader agricultural value chain as Genvor is actively developing applications for its peptide portfolio in animal health and nutrition, where NEPs demonstrate potential to improve feed conversion efficiency, enhance gut …
Effective April 16, 2026, the Company entered into a securities purchase agreement (the “SPA”) with Evergreen Capital Management LLC (“Evergreen”), pursuant to which the Company sold, and Evergreen purchased, (i) a convertible promissory note in the aggregate principal amount of up to $800,000 (the …
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) at June 30, 2026, the end of the period covered by…
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
In connection with the audit of our consolidated financial statements for the year ended September 30, 2025, management identified the following material weaknesses in our internal control over financial reporting, which had not been remediated at June 30, 2026:
During the quarter ended June 30, 2026, management identified the following additional matters relating to the Company’s tax filing, reporting and withholding obligations, which were determined to be material weaknesses:
● Compensation processed through payroll was subject to withholding and reporting. Compensation and other amounts provided to employees in other forms, including amounts deferred, drawn or settled in equity, had not been fully evaluated for their payroll tax and reporting consequences, and the relat…
相对上期删除的文字 · 来源:10-Q · 2026-05-13
The SEC defines the term “disclosure controls and procedures” to mean a company’s controls and other procedure that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within …
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2026, the end of the …
To remediate our internal control weaknesses, management intends to implement the following measures:
● The Company intends to add a sufficient number of independent directors to the board and form an audit committee.
● The Company intends to add sufficient knowledgeable accounting personnel to properly segregate duties and to affect a timely, accurate preparation of the financial statements.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议